It works by: Suppressing appetite signals in the hypothalamus (brain) Slowing gastric emptying food moves more slowly from your stomach to your intestine Stimulating insulin release and reducing glucagon production Stabilizing post-meal blood sugar levels Slowing gastric emptying is the primary driver of most gastrointestinal (GI) side effects
doi:10.1089/thy.2016.0256 Grtner R, Gasnier BC
External resources STEP 1 Trial: Semaglutide in Adults with Overweight or Obesity (NEJM) SURMOUNT-1 Trial: Tirzepatide for Treatment of Obesity (NEJM) NIH BMI Calculator (National Heart, Lung, and Blood Institute) For researchers serious about navigating GLP-1 eligibility and optimizing their treatment protocols, SeekPeptides offers the most comprehensive resource available
They also help people with obesity manage their weight
doi: 10.1186/1475-2891-13-79 9
Semaglutide is FDA-approved for type 2 diabetes management (Ozempic, Rybelsus), cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease (Ozempic), chronic weight management in obesity or overweight with comorbidities (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight (Wegovy)
